Navigation Links
KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
Date:2/26/2013

inity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those related to the company's clinical development of KB003. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that  the company has initiated or plans to initiate; the company's dependence on Sanofi Pasteur for the development and commercialization of KB001-A; the company's ability to successfully complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual prope
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
2. KaloBios Pharmaceuticals Completes Initial Public Offering
3. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
4. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
5. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
6. Dr. Diana Bianchi Presents Data Demonstrating Verinata Healths Proprietary Technology Detects Genetic Abnormalities In Twin Pregnancies
7. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
8. Misonix Presents at MicroCapClub Invitational
9. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
10. Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment
11. Peripheral Vascular Devices Market to 2018 - Increasing Demand for Minimally Invasive Endovascular Procedures Presents Growth Opportunities for Manufacturers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, 2014 ... and Integrated Clinical Trial Services, LLC (ICTS), two ... clinical trials announce that they have formed a ... (i-CTMS). i-CTMS will provide a broad range of ... and medical device companies. i-CTMS will ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... June 25 Perrigo Company (Nasdaq: PRGO ; TASE) announced ... present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging & Leisure Conference ... at the Four Seasons Hotel in Boston .  The presentation will ... , , ...
... 25 PartsSource, the world,s #1 ebusiness solution ... has been honored with the 2010 Manny Award for ... its 13th year, the Manny Award program is committed ... companies for their innovations and best practices. This was the ...
Cached Medicine Technology:Perrigo Company to Present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging and Leisure Conference 2PartsSource Wins 2010 Manny Award for Workplace Environment 2
(Date:12/17/2014)... A group of 127 scientists sent an “open ... to a recent statement by the center that was highly ... the efficacy of all brain exercises. , Signatories to the ... the center’s statement critical of brain exercise companies that overstate ... its case, in a document it had entitled “A Consensus ...
(Date:12/17/2014)... No matter how far modern medicine advances, ... head louse parasite—a common childhood malady and a source ... six and twelve million individuals will suffer an infestation. ... company comes to the rescue, providing an all-natural treatment ... track record of customer service, and effectiveness in getting ...
(Date:12/17/2014)... Mamaroneck, NY (PRWEB) December 17, 2014 ... man who recently brought videos of MIT economist and ... and best-selling author James O’Keefe conducted the interview, which ... “Rich” stated that there was intentional mislabeling in the ... agenda in the bill: A two-hundred-and-fifty billion dollar per ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter , ... of infectious diseases, one worrisome phenomenon is when an illness ... process -- known as zoonosis -- is not uncommon and ... that an animal-borne disease might make inroads into the human ... development -- and the culprits in this case were guinea ...
(Date:12/17/2014)... get more fruits and vegetables at school than they do ... is true for students from wealthier families. These findings ... a healthy boost to poor students, diets, according to the ... students all ate a similar amount of fruits and vegetables ... recently in the journal Preventive Medicine . ...
Breaking Medicine News(10 mins):Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2
... from early magnetic resonance imaging, according to the ... in Canada MRI technology could determine //if performing ... that trauma-induced spinal cord compression on MRIs predict ... spinal cord compression. However, unless surgeons are fairly ...
... condition that affects primarily women. The condition is characterized ... rest and often worsens with physical activity. The cause ... diagnostic tests or cures. A recent study explains that ... for developing chronic fatigue later in life. ,Researchers ...
... a connection between the use of two of the ... reduced risk for // bone fractures. Beta-blockers are commonly ... chest pain, and abnormal heart rhythms. Some heart attack ... attack. Diuretics are used to remove excess water from ...
... undertaken at Wake Forest University Baptist Medical Center researcher ... suggested //that the type of progestin in hormonal therapy ... ,At an annual meeting of the North American ... Williams who is the lead investigator from Wake Forest ...
... Retinitis pigmentosa, a progressive eye disease targeting the light-collecting ... worldwide and can cause // vision loss. Researchers say ... docosahexaenoic acid to vitamin A therapy may not provide ... followed 221 patients, ranging in age from 18 to ...
... Researchers have found that chemotherapy improves survival and reduces the ... // (cancer that has not spread beyond the ovary). ... confined to the ovaries, when five-year survival is 85 percent. ... patients, since eight in 10 patients are adequately treated by ...
Cached Medicine News:Health News:Hormone therapy may affect heart attack severity in women 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: